Navigation Links
NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
Date:9/26/2007

Company to develop for treatment of neurofibromatosis and cancer

NEW YORK, Sept. 26 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc., a privately held New York biotechnology company focused on developing drugs to treat the genetic disorder neurofibromatosis and related sporadic tumors, today announced that it has entered into a definitive agreement with Universite Louis Pasteur (ULP) and the Centre National de la Recherche Scientifique (CNRS) to in-license a novel family of Hsp90 inhibitors.

"Our preliminary evaluation of these compounds has yielded promising results in NF2 and cancer models", said Dr. Allan Rubenstein, CEO of NexGenix. "While targeting the inhibition of protein folding chaperones such as Hsp90 is an approach that is seeing success in clinical trials for cancer, this target has additionally been shown to be potentially promising for a number of therapeutic indications. We intend to evaluate this compound series for the treatment of several disorders."

Under the terms of this agreement, NexGenix will have an exclusive worldwide license to develop and commercialize the technology for human and animal therapeutic and diagnostic use from ULP and CNRS. NexGenix will be responsible for all development and commercialization costs and activities. In return, ULP and CNRS will be entitled to certain maintenance fees, milestone payments and royalties.

The company has additionally entered into a Collaborative Research Agreement with the Institut de Sciences et d'Ingenierie Supramoleculaires at ULP to further understanding of structure activity relationships and opportunities to improve the pharmacokinetic properties of the in-licensed Hsp90 inhibitor compound series. This research program is to be conducted at ULP by Nicolas Winssinger, PhD. Dr. Winssinger is one of the inventors of the compound series and is a member of the NexGenix Scientific Advisory Board.

About NexGenix Pharmaceuticals

NexGenix Pharmaceu
'/>"/>

SOURCE NexGenix Pharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF enters licensing agreements for stem cell products
4. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
5. Software company enters health space with RFID solutions on hold
6. Lucigen Corp. enters global licensing agreement
7. Call centers and customer service: The good, the bad, and the clueless
8. GE Healthcare enters agreement with Canadian health authority
9. Data centers: Buyers beware of over-hyped facilities
10. Data centers: Blowing smoke and raising red flags
11. Prodesse enters patent agreement with Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... the Company,s Investor Day in New ... syndrome (IBS) program, including its novel, oral product ... the keynote presentation, Mark Pimentel , MD, ...
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... , Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers ... (BMSi) test identifies patients with bone fragility fracture ... 160 million people worldwide are at risk of ... today,s standard bone strength test, the DEXA bone ... American Society for Bone and Mineral Research Annual ...
(Date:9/16/2014)... NEW ORLEANS , Sept. 16, 2014 ... Austin, Texas -based cybersecurity company focused on ... 2FA ONE, will support the ability to generate a ... As a pioneer of user-based RFID authentication, ... used for physical access, for many years. RFID authentication ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 32FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2
... Incorporated (Nasdaq: SPEX ), an innovator in ... and providers of technical and regulatory consulting services to ... its President, Dr. Robert Lodder, will be presenting at ... Dr. Lodder will deliver the Company,s corporate presentation ...
... IRVING, Texas, Jan. 5, 2011 Signal Genetics, the ... predictive genetic testing company focused on oncology, and Caris ... enabling precise and personalized healthcare through the highest quality ... announced a new agreement under which Caris Life Sciences ...
... Corporation (Nasdaq: VRNM ), a pioneer in ... today announced that James Levine, Executive Vice President and ... Jaffray Sixth Annual Clean Technology & Renewables Conference.  The ... on Wednesday, January 12, 2011 and will take place ...
Cached Biology Technology:Spherix to Present at Two Upcoming Prominent Finance Conferences 2Spherix to Present at Two Upcoming Prominent Finance Conferences 3Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test 2Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test 3Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 2Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 3
(Date:9/15/2014)... both plants and animals alike. , Understanding just how ... to the design of better drugs for diabetes patients ... vegetables farmers are able to grow. Stanford University researchers ... cell by piecing together proteins slightly wider than the ... determine the size, shape and orientation of one of ...
(Date:9/15/2014)... have found "the most famous wheat gene," a reproductive ... transfer valuable genes from other plants to ... develop wheat varieties with the disease- and pest-resistance traits ... that can reduce crop losses and pesticide use while ... Modified Organisms, or GMOs., "The real exciting part of ...
(Date:9/15/2014)... WASHINGTON A new strategic vision document, released ... Research Program, describes the long-term goals, objectives, and ... scope of work over the next five years ... its initial, short-term activities, to be funded in ... and science policy fellowships. , The $500 ...
Breaking Biology News(10 mins):X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3WSU researchers find 'most famous wheat gene' 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... producing proteins that moonlight, having different roles at different ... killed. The moonlighting activity of one enzyme from the ... of broad-spectrum antibiotics, according to a paper published in ... "Glutamate racemase, or MurI, is an enzyme ...
... many recent reports documenting the therapeutic efficacy of short ... may actually be describing non-specific therapeutic effects related to ... according to a paper in the September 2008 issue ... , a peer-reviewed journal published by Mary Ann Liebert, ...
... NY, Sept. 2, 2008) People concerned about the ... families and communities will have a unique opportunity to ... about the causes, symptoms and progression of such illnesses ... learn about current and potential treatments. In an ...
Cached Biology News:Energy-saving bacteria resist antibiotics 2Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 3
Applications: Western blotting ...
...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Biology Products: